Cardiff Oncology Inc (CRDF) Stock Analysis
Verdict: AVOID
Severe cash burn (-$37.97M FCF loss) leaves CRDF with under 6 months of cash runway, making equity dilution imminent despite insider buys.
Investment score: 37/100
Analysis as of
Is Cardiff Oncology Inc stock worth reviewing? The TradeMates thesis
Cardiff Oncology is a speculative microcap biotech ($105M market cap) developing Onvansertib for KRAS-mutated colorectal cancer. Despite positive insider buys and a recent HC Wainwright upgrade to $9, an unsustainable cash burn (-$37.97M annual FCF) against $17.47M in cash poses immediate dilution risk within six months.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 80/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Cardiff Oncology Inc opportunities and risks
What speaks for CRDF
- Cluster insider buying by C-suite executives at $1.21-$1.45 per share in mid-2026
What speaks against CRDF
- Critical cash runway deficit forcing imminent highly dilutive capital raising
Peers and competitors
- GNLX
- COYA
- PMVP
- CADL
- ATRA
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CRDF | n/a | 198.8x | n/a | 100.0% | -7884.1% | -40.5% |
| GNLX | n/a | 13872.5x | n/a | -1762.5% | -422412.5% | -25.8% |
| COYA | n/a | 14.1x | 1951.4x | 99.9% | -270.2% | -12100.9% |
| PMVP | n/a | 0.0x | n/a | 0.0% | 0.0% | -90.9% |
| CADL | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.9% |
| ATRA | n/a | 13.7x | n/a | 91.4% | -269.4% | -25.7% |
| Peer median | n/a | 13.7x | n/a | 0.0% | -269.4% | -25.8% |
Frequently asked questions about Cardiff Oncology Inc (CRDF)
Is CRDF stock a good investment?
The TradeMates model rates Cardiff Oncology Inc as AVOID with an investment score of 37/100. Cardiff Oncology is a speculative microcap biotech ($105M market cap) developing Onvansertib for KRAS-mutated colorectal cancer. Despite positive insider buys and a recent HC Wainwright upgrade to $9, an unsustainable cash burn (-$37.97M annual FCF) against $17.47M in cash poses immediate dilution risk within six months. This is algorithmic model output, not personal investment advice.
Is CRDF stock a buy?
The TradeMates model verdict for CRDF is AVOID with an investment score of 37/100. Treat this as a model signal to review, not a personal buy recommendation.